Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services' subsidiary, Optival Health Solutions Private Limited, has received a 3-day suspension order for the drug license of a single store located at Seethammapeta Main Road, Visakhapatnam, Andhra Pradesh. The order was issued by the Assistant Director & District Sales Licencing & Enforcing Authority, Visakhapatnam, on July 25, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately Rs 0.69 lakhs from this suspension. The disclosure was made under SEBI's Regulation 30 read with Schedule III.
The impact is negligible for shareholders — a single store, 3-day suspension, and only ~Rs 0.69 lakhs in potential revenue loss is immaterial relative to Medplus's overall operations. No meaningful stock price reaction is expected.